Annual revenue rose from KRW 386 billion in 2022 to KRW 388.8 billion in 2023 (up 0.7%), KRW 477.8 billion in 2024 (up 22.9%) and KRW 536.4 billion in 2025 (up 12.3%), an increase for three consecutive years from 2023 to 2025. 2025 was the largest revenue year in the 2022-2025 period.
Operating profit fell from KRW 38.2 billion in 2022 to KRW 36.1 billion in 2023 (down 5.5%), then rose to KRW 37.2 billion in 2024 (up 3.2%) and KRW 56.1 billion in 2025 (up 50.7%), two consecutive years of growth.
Operating profit growth in 2025 far outpaced revenue growth, which means the margin recovery drove the profit gain. The operating margin was 9.9% in 2022, 9.3% in 2023, 7.8% in 2024 and 10.5% in 2025, the highest of the four years except that 2022 is slightly lower.
Net income attributable to controlling shareholders was KRW 26 billion in 2022, KRW 21.3 billion in 2023 (down 18.1%), KRW 22 billion in 2024 (up 3.3%) and KRW 38.8 billion in 2025 (up 76.4%). Net income including non-controlling interests is reported at the same values for each year.
Quarterly, revenue went from KRW 138.2 billion in Q3 2025 to KRW 154.4 billion in Q4 2025 (up 11.7%) and then fell to KRW 132.1 billion in Q1 2026 (down 14.4%), with operating profit at KRW 12.9 billion in that quarter.
Biologics (KRW 33.4 billion, up 60.1%) and CMO (KRW 33.6 billion, up 22%) grew year on year in Q1 2026. Revenue then rose to KRW 153.3 billion in Q2 2026 and KRW 161.9 billion in Q3 2026, with operating profit of KRW 19.3 billion and KRW 23.9 billion, two consecutive quarters of growth.
The Q3 2026 operating margin was 14.8%, and the company attributed the improvement to a lower cost ratio relative to sales. Controlling-shareholder net income over the last four quarters totaled KRW 49.1 billion.
Operating cash flow moved from -KRW 4.05 billion in 2022 to KRW 8.76 billion in 2023, KRW 56.6 billion in 2024 and KRW 86.4 billion in 2025.
Total equity at year-end 2025 was KRW 436 billion, all attributable to controlling shareholders, total liabilities were KRW 323.5 billion, and the debt-to-equity ratio was 74.2%, the highest of the four years.